
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is expected to launch their new drug Revtorpyk in late 2026, with a management team that is fully prepared and has potential for a healthy launch with their strong network and already secured coverage for over 90% of US medical-benefit lives. With current market-competitive pricing for similar oral agents being around $25,000 per month, Celcuity's IV drug could have a higher net price with only a projected 20% gross-to-net discount, making it more profitable. With a strong launch execution expected and the MT population also expected to be approved in late 2026, Celcuity has a strong opportunity in the fragmented 2L PIK3CA wild-type treatment landscape.
Bears say
Celcuity is a clinical-stage biotechnology company with a promising candidate, gedatolisib, currently in Phase 3 trials for breast cancer and prostate cancer. However, the company faces significant risks, including potential challenges with clinical and regulatory processes, manufacturing, and competition, which could impact the success and profitability of their treatments. Additionally, the company has a negative net worth and currently relies on external funding, which could lead to dilution for existing shareholders.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares